Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities.
- DOI
- 10.3389/fimmu.2026.1922276
- Published
- 2026
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1922276,
title = {Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities.},
author = {Kyriakou A and Minas C and Fantakis A and Tsaousi A and Tsitlakidou A and Meltzanidou P and Lazaridi AM and Fleva A and Giannakou A and Lazaridou E and Patsatsi A},
year = {2026},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2026.1922276},
url = {https://doi.org/10.3389/fimmu.2026.1922276}
}RIS
TY - JOUR TI - Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities. AU - Kyriakou A AU - Minas C AU - Fantakis A AU - Tsaousi A AU - Tsitlakidou A AU - Meltzanidou P AU - Lazaridi AM AU - Fleva A AU - Giannakou A AU - Lazaridou E AU - Patsatsi A PY - 2026 JO - Frontiers in immunology DO - 10.3389/fimmu.2026.1922276 UR - https://doi.org/10.3389/fimmu.2026.1922276 ER -
APA
A, K., C, M., A, F., A, T., A, T., P, M., AM, L., A, F., A, G., E, L., & A, P. (2026). Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1922276
Source records
- pubmed · retrieved 2026-09-25T08:19:16.422Z